Study Of Fesoterodine In Pediatric patients with Overactive Bladder, Ages 8-17 Years
- Conditions
- Overactive bladder (OAB) and Neurogenic Detrusor Over activityTherapeutic area: Not possible to specify
- Registration Number
- EUCTR2014-004161-24-Outside-EU/EEA
- Lead Sponsor
- Pfizer Inc. 235 East 42nd Street, New York, NY 10017
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- A
- Sex
- All
- Target Recruitment
- 21
1.Male or female subjects between the ages of 8 and 17 years (age at time of first dose), inclusive.
2.A total body weight greater than 25 kilogram (kg) or 55 pounds (lbs).
3.Symptoms of urinary frequency (greater than or equal to [=] 8 micturitions on average per 24 hours) and urgency (defined as a sudden and compelling desire to pass urine which is difficult to defer), with or without urgency incontinence, for at least 6 months prior to enrolment or subjects with stable neurological disease and urodynamically confirmed detrusor over activity, who may require intermittent catheterization for management of urinary drainage.
4.Parents or legal guardians must give written informed consent prior to the start of the study. Consent should be obtained from both (if available) of the child’s legal representatives (parents or guardians). In addition, the child’s assent must be obtained.
5.Female subjects must be non-pregnant and non-lactating, and, if applicable, be using an appropriate method of contraception for at least 28 days prior to the first dose of study medication and continue for at least 28 days after the final study drug dose. Subjects of child bearing potential must have confirmed negative urine pregnancy tests taken prior to randomization.
6.Subjects and parents or legal guardians must be thought to be compliant and able to follow the investigator’s instructions. They must be able to visit the clinic on schedule and be both cooperative and reliable.
Are the trial subjects under 18? yes
Number of subjects for this age range: 21
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
1.Subjects required to take concomitant medications that could have interacted with the pharmacokinetics (PK) and pharmacodynamics (PD) of fesoterodine, such as Cytochrome CYP3A4 inhibitors or inducers, CYP2D6 inhibitors, drugs for treatment of OAB, drugs with antispasmodic, parasympathetic, or cholinergic effects, drugs known to affect lower urinary tract function (eg, desmopressin).
2.Subjects who had received any electro stimulation therapy or bladder retraining within 4 weeks of Visit 1 or who were expected to start such therapy during the study period.
3.Subjects with monosymptomatic nocturnal enuresis, or giggle incontinence.
4.Subjects with a clinically significant urinary tract infection at screening.
5.Subjects with a relevant disease with which their urinary symptoms may have been associated like diabetes insipidus, untreated constipation, psychological disorders with impact on bladder function.
6.Subjects with any condition that would have contraindicated or warranted precautions for the use of fesoterodine, including: hypersensitivity to fesoterodine or tolterodine, history of hypersensitivity to peanut or soya, urinary retention, gastric retention, uncontrolled narrow angle glaucoma, myasthenia gravis, severe hepatic impairment, severe ulcerative colitis and toxic megacolon.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To determine the pharmacokinetics of 5-hydroxy-methyltolterodine (5- HMT) in pediatric OAB subjects aged 8-17 years.;Secondary Objective: To examine the influence of subject covariates on the pharmacokinetics of 5-HMT.<br>To assess the safety and tolerability of fesoterodine in pediatric OAB subjects aged 8-17 years.<br>;Primary end point(s): Model-based pharmacokinetic parameter estimates for absorption rate constant, apparent oral clearance and volumes of distribution to predict the area under the plasma drug concentration versus time curve (AUC), maximum concentration (C max), time to reach maximum concentration (T max) and half-life of 5-HMT in pediatric OAB subjects aged 11-17 years.;Timepoint(s) of evaluation of this end point: Day 28, Day 56
- Secondary Outcome Measures
Name Time Method Secondary end point(s): Laboratory tests, post-void residual volume in subjects who are not performing clean intermittent bladder catheterization (CIC) and adverse events.;Timepoint(s) of evaluation of this end point: Baseline, Week 4, Week 8 post-dose